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OBJECTIVES The goal of this research was to test the hypothesis that plasma angiopoietin (Ang-1), its
soluble receptor tie-2, and Ang-2 levels would be abnormal in patients with acute and chronic
congestive heart failure (CHF) when compared with healthy controls.
BACKGROUND Increased plasma vascular endothelial growth factor (VEGF) in CHF is suggestive of excess
angiogenesis—possibly driven by tissue hypoxia. However, other growth factors also have a
major role in angiogenesis, such as those of the angiopoietin family (e.g., Ang-1, which exerts
its activity via its receptor, tie-2, and Ang-2).
METHODS We recruited 39 patients with acute CHF (mean age 67 10 years), 40 patients with chronic
CHF (mean age 63  9 years), and 17 healthy controls (mean age 67  7 years), all in sinus
rhythm. Citrated plasma was analyzed for Ang-1, Ang-2, tie-2, and VEGF by enzyme-linked
immunosorbent assay.
RESULTS Angiopoietin-2 (p  0.001), tie-2 (p  0.05), and VEGF (p  0.05) levels were all higher
in acute CHF compared with controls. The Ang-2 levels were higher in acute CHF
compared with chronic CHF (p  0.001), but there were no significant differences in Ang-1
levels between the groups. The principal significant correlations were between Ang-2 and
tie-2 (Spearman, r  0.407; p  0.0001) and between Ang-2 and ejection fraction (r 
0.241, p  0.043). Although only marginally raised, levels of VEGF correlated with both
Ang-2 (r  0.468, p  0.001) and tie-2 (r  0.569, p  0.001).
CONCLUSIONS We have demonstrated abnormal levels of Ang-2 and tie-2, but normal Ang-1, in both CHF
patients. These abnormalities may, alongside VEGF, indicate a role for these angiogenic
factors in the pathophysiology of CHF. (J Am Coll Cardiol 2004;43:423–8) © 2004 by the
American College of Cardiology Foundation
Congestive heart failure (CHF) is characterized by poor
cardiac output and, consequently, tissue ischemia, the latter
being a powerful stimulus for angiogenesis. Our recent
demonstration of raised plasma levels of the angiogenic
vascular endothelial growth factor (VEGF) in CHF sup-
ports the concept that ongoing angiogenesis is probably
present in this condition (1). More recently, oncology
research has identified other growth factors, such as those of
the angiopoietin (Ang) family, that appear to have a major
role in angiogenesis and metastasis (2–4). The roles of two
members of this family, Ang-1 and Ang-2, are becoming
understood and may act alongside VEGF. The latter is
responsible for the initiation of angiogenesis through re-
cruitment and proliferation of endothelial cells, a process
that Ang-1 potentiates (5).
Angiopoietin-1 and -2 play modulatory roles by binding
a common receptor, the endothelial cell-specific tyrosine
kinase receptor tie-2. Unlike VEGF, Ang-1 and Ang-2 do
not have mitogenic/proliferative properties. More specifi-
cally, Ang-1 is a chemotaxin (6) and, in conjunction with
VEGF, recruits endothelial cells to initiate and accelerate
angiogenesis. In a murine mammary carcinoma model,
Ang-1 is secreted and then bound to the extracellular matrix
(7) where it is ideally situated to mediate cell-to-cell and
cell-to-matrix interaction of capillaries (8,9).
In the presence of VEGF, Ang-2 promotes a rapid
increase in capillary diameter, remodeling of the basal
lamina and new vessel growth evidenced by sprouting of
existing blood vessels, a process that can also be stimulated
by Ang-1 (10). In contrast, if VEGF is inhibited, Ang-2
leads to endothelial cell death and vessel regression (11).
Therefore, Ang-1 potentiates VEGF in the early process of
angiogenesis (i.e., endothelial cell recruitment and prolifer-
ation), as well as adhesion to the basal lamina (10), whereas
Ang-2 promotes vascular remodelling (12). Although hyp-
oxia is known to be a powerful stimulant for angiogenesis,
several studies have shown that hypoxia itself does not
stimulate the expression of Ang-1 (13,14), which is also
known to have antiapoptotic properties via the PI-3 kinase/
Akt/survivin pathway (15).
As hypoxia, endothelial dysfunction/damage (16) and
raised VEGF (1) are present in CHF, we hypothesized
alterations in the angiopoietin family, specifically, Ang-2.
However, as hypoxia does not stimulate the expression of
Ang-1 (13,14), we also hypothesized that Ang-1 would not
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be altered in CHF. This lack of stimulated Ang-1 release as
an “endothelial survival factor” could be partly responsible
for the profound endothelial abnormalities observed in
CHF. We tested our hypothesis by developing an assay for
quantification of Ang-1 and applying this assay (and other
established assays for quantification of Ang-2, tie-2, and
VEGF) in a simple cross-sectional study of acute and
chronic CHF patients, compared with healthy matched
controls.
METHODS
Patients and controls. We recruited 39 patients with acute
CHF, 40 patients with chronic CHF, and 17 healthy
controls, all of whom were in sinus rhythm. Congestive
heart failure was defined according to European Society of
Cardiology guidelines (17). All patients with acute CHF
had evidence of pulmonary edema on chest X-ray in
addition to clinical signs of heart failure. Subjects with CHF
were classified according to the New York Heart Associa-
tion (NYHA) criteria with functional class I to II being no,
or mild, symptoms and class III to IV being moderate to
severe symptoms. Chronic CHF was defined as patients
being in a stable NYHA functional class for at least three
months and were recruited from outpatient clinics.
Echocardiography was undertaken either during admis-
sion or within three months from the time of admission,
and only patients with a documented left ventricular ejec-
tion fraction (LVEF) of 40% (either using M-mode
transthoracic echocardiography or, if there was significant
regional wall motion abnormality, by Simpson’s method)
were included in our analysis.
Exclusion criteria were atrial fibrillation; concomitant
acute coronary syndrome; infection or pyrexial illness; recent
(3 months) myocardial infarction or stroke; chronic and
systemic illnesses including renal failure, hepatic impair-
ment, cancer, and inflammatory connective tissue disease;
inflammatory bowel disease; use of oral steroids; and hor-
mone replacement therapy. Healthy control subjects were
recruited from among healthy hospital staff; spouses of
patients; and from subjects attending the hospital for hernia
repairs, varicose vein procedures, or other relatively minor
operations. All healthy control subjects had no clinical
evidence of vascular, metabolic, neoplastic, diabetic, or
inflammatory disease on careful history, examination, and
routine laboratory tests. Clinical characteristics of patients
and controls are summarized in Table 1.
Patients with acute CHF were venesected within 24 h of
admission to hospital, whereas the separate cohort of
Abbreviations and Acronyms
Ang  angiopoietin
CHF  congestive heart failure
CV  coefficient of variation
ELISA  enzyme-linked immunosorbent assay
HMG-CoA  hydroxymethylglutaryl-coenzyme A
LVEF  left ventricular ejection fraction
NYHA  New York Heart Association
RNA  ribonucleic acid
VEGF  vascular endothelial growth factor
Table 1. Baseline Characteristics of the Study Population
Acute CHF Chronic CHF Controls p Value
n 39 40 17 –
Gender (M:F) 27:12 29:11 4:13 0.001
Age (yrs) 67  10 63  9 67  7 0.254
“Usual” NYHA class
I–II 5 (13%) 22 (55%) —  0.0001
III–IV 34 (87%) 18 (45%) —  0.0001
LVEF (%) 30 (27–35) 30 (30–35) — 0.688
Comorbidity
IHD 23 (59%) 33 (83%) 0  0.0001
HT 22 (56%) 14 (35%) 0  0.0001
DM 15 (38%) 15 (38%) 0 0.93
Cholesterol 4.2  0.2 4.7  0.2 5.7  0.3  0.0001
Cigarette smoking (current) 3 (7.7%) 6 (15%) 1 (5.9%) 0.097
Previous CVA/TIA 0 (0%) 2 (5%) 0 0.239
Treatment
ACE inhibitor or angiotensin receptor blocker 27 (69%) 38 (95%) 0  0.001
Beta-blocker 11 (28%) 20 (50%) 0 0.082
Anti-platelet agent 22 (56%) 30 (75%) 0 0.082
Warfarin 8 (21%) 5 (13%) 0 0.337
Statin 11 (28%) 25 (63%) 0 0.002
Data expressed as mean  1 SD or n (%) unless stated. p values based on chi-square test, except age and cholesterol by analysis
of variance (acute CHF vs. chronic CHF vs. controls) and LVEF by Mann-Whitney U test (acute CHF vs. chronic CHF).
ACE  angiotensin-converting enzyme; CHF  congestive heart failure; CVA  cardiovascular accident; DM  diabetes
mellitus; HT  hypertension; IHD  ischemic heart disease (prior myocardial infarction or symptoms of angina pectoris with
positive exercise tolerance test or coronary disease on angiography); LVEF  left ventricular ejection fraction; NYHA I to IV
New York Heart Association classification (I, asymptomatic; IV, symptoms at rest or with minimal exertion); TIA transient
ischemic attack; —  not estimated.
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patients with chronic CHF were venesected in the outpa-
tient research clinic. Citrated plasma was obtained from
venous blood by centrifugation at 3,000 rpm (1,000 g) for
20 min at 4°C. All aliquots were stored at 70°C to allow
batch analysis.
Laboratory methods. Growth factors and receptors were
measured by enzyme-linked immunosorbent assay (ELISA)
as follows (1,18–20): mouse anti-human Ang-1, biotinyl-
ated goat anti-human Ang-1 and recombinant human
Ang-for the Ang-1 assay, mouse anti-human Ang-2, bio-
tinylated mouse anti-human Ang-2 and recombinant
Ang-2 for the Ang-2 assay, goat anti-human tie-2, biotin-
ylated goat anti-human tie-2 and recombinant human
tie-2/Fc chimera for the tie-2 assay, and rabbit anti-human
VEGF, biotinylated goat anti-human VEGF, biotinylated
goat antihuman Flt-1 and recombinant human VEGF-165
for the VEGF assays (all obtained from R&D Systems,
Abingdon, Oxfordshire, United Kingdom). The precise
methods for VEGF, tie-2, and Ang-2 are available else-
where (1,19,20).
Development of the Ang-1 assay. As the Ang-1 assay is
novel (18), full details are provided. The ELISA system was
based on a sandwich noncompetitive ELISA, consisting of
an anti-human Ang-1 antibody (capture antibody) and a
biotinylated goat anti-human Ang-1 (detection system).
ExtrAvidin peroxidase (Sigma, Poole, United Kingdom)
was used to amplify the antibody-antigen reaction, and the
color was developed using ortho-phenylenediamine dihy-
drochloride tablets (Sigma). Mouse anti-human Ang-1
antibody was adsorbed onto 96-well microtitre immunoas-
say plates for a minimum of 15 h at 4°C (i.e., overnight) at
concentrations ranging from 0.5 to 10 g/ml. Biotinylated
goat anti-human antibody at concentrations ranging from
250 to 500 ng/ml was combined to measure plasma Ang-1.
Optimum titres were determined using checkerboard titra-
tion, seeking high optical density from standards and
minimum optical density from blanks. Standard curves were
generated using recombinant human Ang-1 (rHAng-1)
protein at 0 to 1,000 ng/ml.
The final protocol for Ang-1 ELISA is as follows (18):
First, 96-well microtitre immunoassay plates (Dynex Lab-
systems, Ashford, Middlesex, United Kingdom) were
coated with 100 l/well of 2 g/ml mouse anti-human
Ang-1 in 0.05 mol/l carbonate/bicarbonate buffer (pH 9.6)
for a minimum of 15 h at 4°C. Plates were then washed
three times in assay buffer (0.05% Tween 20 in 0.1 mol/l
phosphate buffered saline, pH 7.2) and in between each
subsequent incubation period. After blocking for 2 h at
room temperature with 5% dried powdered milk (Marvel,
Cadbury, Birmingham, United Kingdom) in phosphate
buffered saline-Tween (200 l/well), recombinant human
Ang-1 standards (ranging from 0 to 100 ng/ml) and plasma
samples were added in duplicate (100 l/well) for 2 h at
room temperature; 100 l/well biotinylated detection anti-
body (500 ng/ml) was then added for a further 2 h at
room temperature. ExtrAvidin peroxidase (1:1,000 dilution)
was added for 45 min at room temperature (100 l/well)
before the development of color with 10 mg ortho-
phenylenediamine dihydrochloride dissolved in 20 ml
0.05 mol/l citrate buffer (pH 5.0) and 10 l 1 mol/l hydrogen
peroxide. The reaction was stopped using 1 mol/l hydro-
chloric acid and the absorbance read at 492 nm.
The intra-assay coefficient of variation was 3.87% at
20 ng/ml Ang-1 (n  24), and 4.13% at 40 ng/ml.
Interassay coefficient of variation was 9.45% at 20 ng/ml
(n  8) and 9.78% at 40 ng/ml (n  7). The lower limit of
sensitivity for the assay was a concentration of 1 ng/ml
Ang-1.
Power calculation and analysis. We have previously re-
ported plasma VEGF to be raised by a factor of 2 in 53
patients with chronic CHF and almost 3 in 77 with acute
CHF, compared with 37 healthy controls, a difference that
was most significant (p  0.001) (1). Therefore, seeking
more modest significance (analysis of variance, p  0.05) in
the present study, we set our power calculation at a
minimum of 17 subjects per group (sample size  51) to
enable us to detect a difference of 1 SD with 1-  0.8 and
p  0.05 between groups. Data were analysed by the
Shapiro-Wilks test to determine distribution. Normally
distributed data are expressed as mean and SD. As the data
for LVEF, VEGF, and Ang/tie-2 were not normally
distributed, values are expressed as median (interquartile
range). Baseline cross-sectional data between acute CHF
patients, chronic CHF outpatients, and healthy controls
were analyzed by analysis of variance, the Mann-Whitney or
the Kruskal-Wallis test as appropriate, with between group
comparisons by Tukey’s post-hoc test (after log transforma-
tion). Correlations were performed using Spearman’s rank
correlation method. Stepwise multiple regression analysis
was used to determine the predictors of abnormal research
indexes. A value of p  0.05 was considered statistically
significant.
RESULTS
Cross-sectional analyses and correlations. Median plasma
levels of Ang-1 in CHF patients were not significantly different
than healthy controls (p  0.07), but median Ang-2 levels were
significantly elevated in CHF (p  0.0001), with significant
differences in Ang-2 levels between acute CHF, chronic CHF,
and healthy controls (each, p 0.05) (Table 2, Fig. 1). There was
a significant overall variance in levels of tie-2 levels between the
three groups, with the difference between the controls and the
acute CHF patients being significant (p 0.05) (Table 2, Fig. 2).
There was also significant overall variance in levels of VEGF (p
0.04), but there were no statistically significant intergroup
differences.
The principal significant correlations were between
Ang-2 and tie-2 (Spearman r  0.407, p  0.0001) and
between Ang-2 and ejection fraction (r  0.241, p 
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0.043). Although only marginally raised, levels of VEGF
correlated with both Ang-2 (r  0.468, p  0.001) and
tie-2 (r  0.569, p  0.001). There were no statistically
significant differences in plasma levels of any of the research
indexes when the subgroups of patients with NYHA func-
tional class II were compared with NYHA functional class
III/IV (data not shown).
Effects of associated comorbidity. Because the prevalence
of comorbid diseases and the proportion of various treat-
ment therapies at baseline differed in both groups of CHF
(Table 1), we compared the values of Ang-1, Ang-2, tie-2,
and VEGF with the past medical histories (ischemic heart
disease, hypertension, cerebrovascular accident, diabetes,
cholesterol level, smoking history) and various treatment
therapies (beta blockers, angiotensin-converting enzyme
inhibitors/angiotensin-1 receptor blockers, statin, warfarin,
antiplatelet therapy) within the acute and chronic CHF
groups. Using univariate analysis, high levels of Ang-2 were
correlated with lower cholesterol levels (r  0.337, p 
0.003) and (unsurprisingly) statin use (r  0.310, p 
0.005). None of the markers were significantly influenced by
age, gender, or past medical history (all p  NS, data not
shown).
Stepwise multiple regression analyses. Using stepwise mul-
tiple regression analyses, cholesterol level and hydroxymethyl-
glutaryl-coenzyme A (HMG-CoA) reductase inhibitor use,
but not NYHA functional class, independently predicted
Ang-2 levels in CHF (p  0.0001 and p  0.005, respec-
tively). Only NYHA functional class independently predicted
Ang-1 level (p  0.012).
DISCUSSION
Published data on the role of the Ang/tie-2 system in
cardiovascular diseases are limited. Most of our knowledge
regarding the angiopoietins has come from oncology studies
where angiogenesis is a prerequisite for tumor growth and
metastasis. Indeed, Ang-2 has been shown to be a marker of
a poor prognosis in breast cancer and non-small cell lung
cancer (4,21). In the present paper, we describe a new assay
for Ang-1 and, in addition, have demonstrated (for the first
time in the literature) very abnormal levels of Ang-2 and
tie-2, but normal Ang-1, in CHF. Vascular endothelial
growth factor was marginally raised in the patients, suggest-
ing that Ang-2 may be more relevant to the pathophysiol-
ogy of this disease. In addition, there was a significant
correlation between Ang-2 and tie-2.
That Ang-1 is not raised in CHF is consistent with
currently held views that its secretion is not stimulated by
hypoxia, as demonstrated in animal studies (13,14,22).
Angiopoietin-1 has been shown to have antiapoptotic ef-
fects on endothelial cells through the activation of phospha-
tidylinositol 3-kinase (15,23). This, in turn, stimulates the
survival serine-threonine kinase, Akt, activation that is a
requisite of survivin upregulation (24). The up-regulation of
survivin protects endothelial cells from death-inducing
stimuli. It is possible that the lack of stimulated Ang-1
secretion in CHF is partly responsible for the degree of
endothelial damage observed in this condition (16).
The role of VEGF and the Ang in CHF remains unclear.
Patients in chronic, stable CHF are frequently not hypoxic,
yet plasma Ang-2 is elevated. Rather than just being purely
Figure 1. Angiopoietin-2 levels in acute congestive heart failure (CHF),
chronic CHF, and controls. The boxes indicate the interquartile range with
median value. The asterisks indicate outlying data points.
Figure 2. Plasma tie-2 levels in acute congestive heart failure (CHF),
chronic CHF, and controls. The boxes indicate the interquartile range with
median value. The asterisks indicate outlying data points.
Table 2. Ang-1, Ang-2, Ang Receptor Tie-2, and VEGF Levels in CHF
Variable
Acute CHF
(n  39)
Chronic CHF
(n  40)
Controls
(n  17) p Value
Ang-1 (ng/ml) 10 (4–28) 15 (8–31) 8 (5–17) 0.07
Ang-2 (ng/ml) 16 (10–20 7.6 (6–11) 5 (4.0–5.8)  0.0001
Tie-2 (ng/ml) 18 (14–26) 14 (12–24) 10 (8–13) 0.001
VEGF (pg/ml) 300 (200–600) 250 (40–575) 220 (80–270) 0.04
Data expressed as median (interquartile range); p value from the Kruskal-Wallis test.
Ang  angiopoietin; CHF  congestive heart failure; VEGF  vascular endothelial growth factor.
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mediators in angiogenesis, VEGF and Ang may, conceiv-
ably, play a role in endothelial homeostasis. Certainly,
profound endothelial damage/dysfunction is associated
with CHF as evident (for example) by elevated levels of
von Willebrand factor (1,25). In addition, CHF is associ-
ated with (modestly) raised VEGF and now, Ang-2. There-
fore, the VEGF and Ang-2 may mediate endothelial
proliferation, not just in angiogenesis but also in endo-
thelial repair. Indeed, VEGF has already been shown
to stimulate endothelial proliferation and accelerate re-
endothelialization after angioplasty-induced endothelial de-
nudation in rabbit carotid arteries (26). Moreover, Ang-1
levels in CHF were not significantly different from controls,
despite Ang-1-induced tie-2 phosphorylation being essen-
tial to initiate angiogenesis (10,27). However, there are also
studies showing that Ang-2 and VEGF alone are sufficient
for angiogenesis (12,28,29).
Several studies have shown that HMG-CoA reductase
inhibitors have both proangiogenic and antiangiogenic ef-
fects. One showed a biphasic effect, being proangiogenic at
low concentrations but antiangiogenic at high concentra-
tions (30–32). In our study, there was a negative correlation
between serum cholesterol level and Ang-2; HMG-CoA
reductase inhibitor use was also associated with lower
Ang-2. Clearly, this could be explained by the significantly
greater use of HMG-CoA reductase inhibitor in chronic
CHF compared with acute CHF. Unfortunately, we do not
have serum concentrations of HMG-CoA reductase inhib-
itors available to draw any other conclusions, as neither their
use nor Ang-2 correlated with outcome.
This study is limited by the single, global measurement of
the angiopoietins and their soluble receptor. Therefore, we
are unable to determine the levels of these mediators locally
where angiogenesis occurs, nor the precise source or stimuli
for these molecules in CHF. The Ang-2 messenger ribo-
nucleic acid (RNA) expression in response to hypoxia is
seen in microvascular endothelial cells and not macrovascu-
lar or lymphatic bovine endothelial cells (14). On the other
hand, Ang-1 is secreted by periendothelial cells and acts in
a paracrine manner. Hence, the plasma levels may not be
representative of the cell biology of vasculogenesis, although
several studies have shown that Ang-1 messenger RNA
expression is not increased in a hypoxic environment.
Secondly, we do not have data on angiopoietin messenger
RNA levels in order to relate them to plasma levels. Indeed,
we do not have direct evidence that angiogenesis, per se,
actually occurs in CHF. We presume that, as there is
hypoxia and elevated angiogenic factors, that angiogenesis
takes place, but, as previously mentioned, these factors may
also have a role in endothelial repair. While the lack of a
clear and strong association with clinical indexes of ejection
fraction and NYHA class (which would have been expected)
raises the question of the value of these markers in a clinical
setting, the abnormalities in the angiopoietin system may
have implications for the (complex) pathophysiology of
CHF. Ongoing prospective studies in our group are cur-
rently examining the relation of the angiopoietin system to
etiology, treatments (e.g., angiotensin-converting enzyme
inhibitors, beta-blockers, statins, and so on), and prognosis
in CHF.
Conclusions. Elevated levels of Ang-2 (but not Ang-1)
and its receptor tie-2 are present in both acute and chronic
CHF patients that may, alongside VEGF, indicate a role for
these angiogenic factors in the pathophysiology of CHF.
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